(Q46022237)

18 December 2017

title

Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT. (English)

1 reference

18 December 2017

1 reference

Wolfgang Luboldt

1 reference

18 December 2017

Klaus Zöphel

1 reference

18 December 2017

Gerd Wunderlich

1 reference

18 December 2017

Andrij Abramyuk

1 reference

18 December 2017

Hans-Joachim Luboldt

1 reference

18 December 2017

Joerg Kotzerke

1 reference

18 December 2017

publication date

7 May 2009

1 reference

18 December 2017

Molecular Imaging and Biology

published in

1 reference

18 December 2017

volume

1 reference

18 December 2017

issue

1 reference

18 December 2017

page(s)

78-84

1 reference

18 December 2017

Treatment options for hormone-refractory prostate cancer

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11307-009-0230-3

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11307-009-0230-3

Growth hormone inhibitors in prostate cancer: a systematic analysis

21 January 2018

1 reference

12 December 2020

Do neuroendocrine cells in human prostate cancer express androgen receptor?

1 reference

12 December 2020

Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors

1 reference

12 December 2020

Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours

1 reference

12 December 2020

Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma

1 reference

12 December 2020

Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer

1 reference

12 December 2020

Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report.

1 reference

12 December 2020

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

1 reference

12 December 2020

Cure of neuroendocrine carcinoma by peptide receptor radionuclide therapy

1 reference

12 December 2020

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

1 reference

12 December 2020

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.

1 reference

12 December 2020

Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role

1 reference

12 December 2020

The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research

1 reference

12 December 2020

Neuroendocrine tumors. Peptide receptor radionuclide therapy

1 reference

12 December 2020

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

1 reference

12 December 2020

Neuroendocrine cells in tumour growth of the prostate

1 reference

12 December 2020

Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.

1 reference

12 December 2020

EAU guidelines on prostate cancer

1 reference

12 December 2020

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

1 reference

12 December 2020

Processing of generator-produced 68Ga for medical application.

1 reference

12 December 2020

Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.

1 reference

12 December 2020

Identification of prognostic biomarkers for prostate cancer

1 reference

12 December 2020

Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases

1 reference

12 December 2020

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake

1 reference

12 December 2020

Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group

1 reference

12 December 2020

Molecular biology of somatostatin receptors

1 reference

12 December 2020

Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors

1 reference

12 December 2020

Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses

1 reference

12 December 2020

GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog

1 reference

12 December 2020

Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines

1 reference

12 December 2020

Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy

1 reference

12 December 2020

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data

1 reference

12 December 2020

10.1007/S11307-009-0230-3

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017